Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaginal live four-strain Lactobacillus capsule
- Development stage
- Phase 2
- Lead developer
- Sichuan Yanyang Biotechnology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
vaginal live four-strain Lactobacillus capsule (KAL-001) is an investigational live biotherapeutic product (LBP) developed by Sichuan Anaerobic Biotechnology and licensed to Inner Mongolia Shuangqi Pharmaceutical (a subsidiary of Wedge Industrial) for development and commercialization in Greater China. The product consists of four distinct strains of live Lactobacillus selected from a proprietary library of vaginal microbiota to synergistically restore and maintain the vaginal microflora. KAL-001 is designed to treat vaginal dysbiosis by acting as a microbiome modulator and bacterial replacement therapy. It is currently in Phase III clinical development for the treatment and prevention of recurrence of bacterial vaginosis (BV) and in Phase II clinical development for postmenopausal atrophic vaginitis.
- Other names
- Viable Lactobacillus Quadruple (Sichuan Yanyang Biotechnology)vaginal live quadruple Lactobacillus capsulevaginal quadruple Lactobacillus live capsule阴道用四联乳杆菌活菌胶囊
Beyond the preview
Go deeper on vaginal live four-strain Lactobacillus capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaginal live four-strain Lactobacillus capsule.